(Z)-(1S,4R,6S,14S,18R)-14-Cyclopentyloxycarbonylamino-18-(7-methoxy-2-methoxycarbonyl-quinolin-4-yloxy)-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-7-ene-4-carboxylic acid methyl ester | 300831-74-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (Z)-(1S,4R,6S,14S,18R)-14-Cyclopentyloxycarbonylamino-18-(7-methoxy-2-methoxycarbonyl-quinolin-4-yloxy)-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-7-ene-4-carboxylic acid methyl ester
• 英文别名: methyl (1S,4R,6S,7Z,14S,18R)-14-(cyclopentyloxycarbonylamino)-18-(7-methoxy-2-methoxycarbonylquinolin-4-yl)oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylate
• CAS: 300831-74-7
• 化学式: C₃₇H₄₆N₄O₁₀
• 分子量: 706.793
• InChiKey: DHMMBXXKHLNJQE-SWDWQWCGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  51
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  172
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  (Z)-(1S,4R,6S,14S,18R)-14-Cyclopentyloxycarbonylamino-18-(7-methoxy-2-methoxycarbonyl-quinolin-4-yloxy)-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-7-ene-4-carboxylic acid methyl ester 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 1.0h， 生成 Sodium; 4-((Z)-(1S,4R,6S,14S,18R)-14-cyclopentyloxycarbonylamino-4-methoxycarbonyl-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-7-en-18-yloxy)-7-methoxy-quinoline-2-carboxylate
  参考文献：
  名称：

  Macrocyclic peptides active against the hepatitis C virus

  摘要：

  式I的化合物：其中R1是羟基或NHSO2R1A，其中R1A是（C1-8）烷基，（C3-7）环烷基或（C1-6）烷基-（C3-7）环烷基，这些都可以选择地被卤素，氰基，硝基，O（C1-6）烷基，酰胺基，氨基或苯基取代1到3次，或者R1A是C6或C10芳基，它可以选择地被卤素，氰基，硝基，（C1-6）烷基，O（C1-6）烷基，酰胺基，氨基或苯基取代1到3次；R2是（C5-6）环烷基，R3是环戊基；或其药用可接受的盐，用作HCV NS3蛋白酶的抑制剂。

  公开号：

  US20030224977A1
• 作为产物：
  描述：

  1-烯庚醛 在 1,2-bis[(2S,5S)-2,5-diethylphospholano]benzene(1,5-cyclooctadiene)rhodium(I) trifluoromethanesulfonate 盐酸 、 4-二甲氨基吡啶 、 偶氮二甲酸二异丙酯 、 氢气 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 吡啶 、 乙醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、310.26 kPa 条件下， 反应 87.5h， 生成 (Z)-(1S,4R,6S,14S,18R)-14-Cyclopentyloxycarbonylamino-18-(7-methoxy-2-methoxycarbonyl-quinolin-4-yloxy)-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-7-ene-4-carboxylic acid methyl ester
  参考文献：
  名称：

  Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans

  摘要：

  The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation.

  DOI：

  10.1021/ol0489907

文献信息

• Macrocyclic peptides active against the hepatitis C virus
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20030224977A1

  公开（公告）日：2003-12-04

  Compounds of formula I: 1 wherein R 1 is hydroxy or NHSO 2 R 1A wherein R 1A is (C 1-8 )alkyl, (C 3-7 )cycloalkyl or {(C 1-6 )alkyl-(C 3-7 )cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C 1-6 )alkyl, amido, amino or phenyl, or R 1A is C 6 or C 10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C 1-6 )alkyl, O(C 1-6 )alkyl, amido, amino or phenyl; R 2 is (C 5-6 )cycloalkyl and R 3 is cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

  式I的化合物：其中R1是羟基或NHSO2R1A，其中R1A是（C1-8）烷基，（C3-7）环烷基或（C1-6）烷基-（C3-7）环烷基，这些都可以选择地被卤素，氰基，硝基，O（C1-6）烷基，酰胺基，氨基或苯基取代1到3次，或者R1A是C6或C10芳基，它可以选择地被卤素，氰基，硝基，（C1-6）烷基，O（C1-6）烷基，酰胺基，氨基或苯基取代1到3次；R2是（C5-6）环烷基，R3是环戊基；或其药用可接受的盐，用作HCV NS3蛋白酶的抑制剂。
• Structure−Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061
  作者：Montse Llinàs-Brunet、Murray D. Bailey、Gordon Bolger、Christian Brochu、Anne-Marie Faucher、Jean Marie Ferland、Michel Garneau、Elise Ghiro、Vida Gorys、Chantal Grand-Maître、Ted Halmos、Nicole Lapeyre-Paquette、Francine Liard、Martin Poirier、Manon Rhéaume、Youla S. Tsantrizos、Daniel Lamarre

  DOI：10.1021/jm0342414

  日期：2004.3.1

  From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified. Structure-activity relationship studies were per-formed focusing on optimizing the N-terminal carbamate and the aromatic substituent on the (4R)-hydroxyproline moiety. Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified. BILN 2061 was selected as the best compound, the first NS3 protease inhibitor reported with antiviral activity in man.
• US7504378B2
  申请人：——

  公开号：US7504378B2

  公开（公告）日：2009-03-17
• Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans
  作者：Anne-Marie Faucher、Murray D. Bailey、Pierre L. Beaulieu、Christian Brochu、Jean-Simon Duceppe、Jean-Marie Ferland、Elise Ghiro、Vida Gorys、Ted Halmos、Stephen H. Kawai、Martin Poirier、Bruno Simoneau、Youla S. Tsantrizos、Montse Llinàs-Brunet

  DOI：10.1021/ol0489907

  日期：2004.8.1

  The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation.